Contact Us

DESTINATION NEWS

TEDA Celebrates 40 Years of Pioneering Innovation, Inclusive Opening-up, and Synergistic development

Dec 10, 2024

TIANJIN,China,Dec. 7,2024-- TheTianjin Economic-Technological Development Area("TEDA"),established in 1984 upon the approval of China\'s State Council,is celebrating its 40th anniversary. Th

Blokees' TRANSFORMERS Figures Take the Spotlight at Cybertron Con 2024, Captivating TRANSFORMERS Fans

Dec 10, 2024

SHANGHAI,Dec. 7,2024-- On December 6,the much-anticipated event for many TRANSFORMERS fans,2024 TransformersCybertron Con,officially opens. As an official partner of TRANSFORMERS,Blokees will showcase

Global Times: Clay Figure Zhang's works naturally reflect spiritual state of the times

Dec 10, 2024

BEIJING,Dec. 8,2024-- From exquisite craftsmanship to traditional Chinese medicine,from solemn rituals to vibrant folk art,intangible cultural heritage weaves the tapestry of Chinese identity. For cen

GCCAC advances cooperation with BRI partners

Dec 10, 2024

FUZHOU,China,Dec. 7,2024-- The 2024 Belt and Road Commerce Chambers and Associations Conference (GCCAC) was held in Fuzhou,East China\'s Fujian Province on Thursday.

NYXI Unveils the NYXI Flexi Game Controller: A New Era of Customizable Button Layouts

Dec 10, 2024

HONG KONG,Dec. 7,2024--Today,NYXI officially announces the global launch of the NYXI Flexi Wireless Game Controller,designed to deliver a seamless and customizable gaming experience across multiple pl

2024 ASH Oral Presentation----Abbisko presents promising preliminary phase 2 study results of pimicotinib in the treatment of Chronic Graft-versus-Host Disease (cGvHD) at the 66th ASH Annual Meeting

Dec 10, 2024

SHANGHAI,Dec. 9,2024-- December 8,2024,Abbisko Therapeutics (HKEX: 02256) announced the presentation of preliminary Phase 2 study results for pimicotinib (ABSK021) in patients with chronic Graft-versu

1 ... 181 182 183 184 185 186 187 ... 347